Moteur de recherche d’entreprises européennes
Financement de l’UE (9 986 186 €) : Le Consortium européen pour l’infrastructure de protéomique Hor01/01/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Le Consortium européen pour l’infrastructure de protéomique
In life sciences research, proteomics technologies promise to be even more revolutionary than genomics for understanding the molecular mechanisms of complex biological systems and their (mal-)functions in health and disease. As a result, there is a strongly growing need for the integration of proteomic technologies into world-class life sciences research programs in medicine, agriculture, food, biotechnology, and materials. The European Proteomics Infrastructure Consortium providing Access (EPIC-XS) brings together a consortium of world-leading, highly innovative European proteomics facilities with the shared goal of supporting excellent life sciences research in Europe. This will be achieved by providing access to cutting-edge proteomics facilities, and by developing and implementing novel mass spectrometry based proteomics and bioinformatics approaches to shape the future life sciences research in Europe. The Transnational Access in EPIC-XS consists of around 2400 days of access to state-of-the-art proteomics facilities, corresponding to around 150 user projects, which will be evaluated by an independent review panel to ensure excellence, and to match users with the best facility for their challenging research questions. The cutting-edge Joint Research Activities in EPIC-XS are built on the extremely strong innovation track record of the consortium members, and will address bottlenecks in, and develop novel approaches for, future-oriented efforts in computational and structural proteomics, analysis of higher-order proteome organization, multi-omics integration, and translational/clinical proteomics and personalized/precision medicine. EPIC-XS will provide users with unrivalled access to world-leading facilities and expertise, while simultaneously extending Europe’s leading international role in the. EPIC-XS meets the widespread current demands for user access, addresses present bottlenecks in the field and will open up entirely new perspectives in proteomics.
| Centre National de la Recherche Scientifique CNRS | 0,00 € |
| EBERHARD KARLS UNIVERSITAET TUEBINGEN | 209 750 € |
| EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH | 1 202 916 € |
| EUROPEAN MOLECULAR BIOLOGY LABORATORY | 266 750 € |
| Forschungsinstitut FUR Molekulare Pathologie GmbH | 208 500 € |
| Fundacio Centre de Regulacio Genomica | 523 349 € |
| Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos III | 480 782 € |
| Idryma Technologias Kai Erevnas | 70 500 € |
| Institut Pasteur | 499 282 € |
| Istituto Europeo Di Oncologia Srl | 488 125 € |
| Kobenhavns Universitet | 1 206 964 € |
| Kungliga Tekniska Hoegskolan | 473 313 € |
| Masarykova Univerzita | 0,00 € |
| Mikrobiologicky Ustav AV CR V.V.I | 474 125 € |
| TARTU ULIKOOL | 70 500 € |
| TECHNISCHE UNIVERSITAET MUENCHEN | 524 203 € |
| The Chancellor Masters and Scholars of the University of Cambridge | 120 500 € |
| UNIVERSITEIT UTRECHT | 1 745 001 € |
| Universitetet I Bergen | 70 500 € |
| VIB VZW | 1 351 127 € |
https://cordis.europa.eu/project/id/823839
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.